Regulating TRAIL Receptor-Induced Cell Death at the Membrane: A Deadly Discussion

Title: Regulating TRAIL Receptor-Induced Cell Death at the Membrane: A Deadly Discussion

Volume: 6 Issue: 3

Author(s): Sarah Shirley, Alexandre Morizot and Olivier Micheau

Affiliation:

Keywords: chemotherapy, death domain, death effector domain, DISC, FADD, c-FLIP,, scaffold, TRAIL, TRAIL-R4, APO2-L

Abstract: The use of TRAIL/APO2L and monoclonal antibodies targeting TRAIL receptors for cancer therapy holds great promise, due to their ability to restore cancer cell sensitivity to apoptosis in association with conventional chemotherapeutic drugs in a large variety of tumors. TRAIL-induced cell death is tightly regulated right from the membrane and at the DISC (Death-Inducing Signaling Complex) level. The following patent and literature review aims to present and highlight recent findings of the deadly discussion that determines tumor cell fate upon TRAIL engagement.

Cite this article as:

Shirley Sarah, Morizot Alexandre and Micheau Olivier, Regulating TRAIL Receptor-Induced Cell Death at the Membrane: A Deadly Discussion, Recent Patents on Anti-Cancer Drug Discovery 2011; 6 (3) . https://dx.doi.org/10.2174/157489211796957757